Your browser doesn't support javascript.
loading
Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report.
John, Alexius; Vick, Joanna; Sarker, Sarah; Middleton, Elizabeth; Cartwright, Elizabeth; Manickavasagar, Thubeena; McMahon, David; Tokaca, Nadza; Popat, Sanjay.
Afiliación
  • John A; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • Vick J; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • Sarker S; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • Middleton E; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • Cartwright E; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • Manickavasagar T; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • McMahon D; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • Tokaca N; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
  • Popat S; Royal Marsden Hospital, Lung Unit, London, United Kingdom.
JTO Clin Res Rep ; 5(7): 100689, 2024 Jul.
Article en En | MEDLINE | ID: mdl-39091593
ABSTRACT
Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system-active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JTO Clin Res Rep Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JTO Clin Res Rep Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos